Letter to the Editor: From association to mechanism - advancing the understanding of small intestinal bacterial overgrowth in acute pancreatitis

Abstract

Small intestinal bacterial overgrowth (SIBO) has emerged as a potential contributor to gastrointestinal dysfunction and systemic inflammation in acute pancreatitis (AP). The recent study by Kumbar et al provides important prospective evidence demonstrating a substantially higher prevalence of SIBO among patients with AP than healthy controls and identifies several clinical variables associated with bacterial overgrowth. Rather than reiterating the methodological limitations acknowledged by the authors, we discuss how these findings fit within the evolving understanding of the gut-pancreas axis and highlight emerging opportunities for precision microbiome research in AP. Particular attention is given to intestinal methanogen overgrowth, a biologically distinct entity that may influence intestinal motility, disease phenotype, and therapeutic response. We further outline future research priorities, including longitudinal microbiome profiling, integration of microbial biomarkers with clinical severity indices, and phenotype-directed therapeutic strategies. These perspectives extend the clinical implications of the index study and underscore the need to move beyond prevalence estimates toward mechanistic and translational investigations that clarify the causal role of microbial dysbiosis in AP.

Key Words: Small intestinal bacterial overgrowth; Acute pancreatitis; Glucose hydrogen breath test; Gut-pancreas axis; Dysbiosis; Methane; Intestinal motility; Gut barrier dysfunction

Core Tip: The prospective study by Kumbar et al represents an important step toward understanding the relationship between small intestinal bacterial overgrowth and acute pancreatitis. Beyond confirming a high prevalence of small intestinal bacterial overgrowth, the findings raise broader questions regarding host-microbiome interactions, intestinal methanogen overgrowth, microbial biomarkers of disease severity, and precision therapeutic strategies. Future studies integrating breath testing with microbiome sequencing, metabolomic profiling, and longitudinal clinical assessment may determine whether microbial alterations are merely markers of disease severity or active contributors to pancreatic inflammation and systemic complications.

TO THE EDITOR

We read with considerable interest the recent article by Kumbar et al[1]. Describing the frequency and predictors of small intestinal bacterial overgrowth (SIBO) in patients with acute pancreatitis (AP) using the glucose hydrogen breath test. Their observation that SIBO occurred substantially more frequently in AP than in healthy individuals and increased with disease severity provides important prospective evidence supporting the growing recognition that intestinal microbial disturbances accompany pancreatic inflammation.

Although the authors appropriately discussed several methodological limitations of their study, we believe that the broader scientific significance of their findings extends beyond diagnostic performance alone. Emerging evidence increasingly suggests that alterations in the intestinal ecosystem should not be regarded merely as secondary consequences of AP but as dynamic components of disease biology capable of modulating intestinal permeability, innate immune activation, and systemic inflammatory responses through the gut-pancreas axis[2-5]. This evolving paradigm provides an opportunity to interpret the study within a broader translational framework rather than solely as an investigation of SIBO prevalence.

Particularly noteworthy is the finding of a higher prevalence of methane-predominant breath profiles among patients with AP. Recent consensus statements distinguish intestinal methanogen overgrowth (IMO) from conventional hydrogen-predominant SIBO because methane is produced predominantly by methanogenic archaea rather than bacteria[6,7]. Recognition of IMO as a distinct biological entity may have important implications for intestinal motility, persistence of ileus, symptom burden, and therapeutic responsiveness during AP, yet these aspects remain largely unexplored in patients with AP[6-8].

Rather than revisiting methodological concerns already acknowledged in the original article, we seek to place the findings of Kumbar et al[1] within the rapidly expanding literature on host-microbiome interactions and precision gastroenterology. We believe this perspective highlights several emerging research priorities, including longitudinal characterization of intestinal microbial dynamics, integration of microbiome-derived biomarkers into existing severity prediction models, and development of microbiome-guided therapeutic interventions[3-5,9]. Such investigations may ultimately determine whether microbial dysbiosis functions primarily as a marker of disease severity or represents a modifiable contributor to disease progression.

CURRENT PERSPECTIVES

Gut-pancreas axis: From microbial association to mechanistic insight

The association between intestinal dysbiosis and AP has traditionally been interpreted primarily as a consequence of impaired intestinal motility, disruption of epithelial barrier integrity, and systemic inflammation. However, growing experimental and clinical evidence suggests that this relationship is bidirectional, whereby alterations in the intestinal microbiome may actively amplify pancreatic injury through immune modulation and metabolic signalling rather than merely reflecting disease severity[2-5].

Disruption of the intestinal epithelial barrier during the early phase of AP facilitates translocation of microbial products, including lipopolysaccharide, peptidoglycan fragments, and other microbial metabolites into the systemic circulation. These molecules activate innate immune pathways through pattern-recognition receptors such as Toll-like receptors and nucleotide-binding oligomerization domain-like receptors, thereby perpetuating pancreatic inflammation and systemic immune activation[2,3]. Consequently, microbial dysbiosis should increasingly be considered a potential contributor to disease progression rather than simply an epiphenomenon.

Viewed from this perspective, the findings reported by Kumbar et al[1] provide more than epidemiological evidence of bacterial overgrowth. The progressive increase in SIBO prevalence across disease severity categories supports the hypothesis that intestinal microbial alterations evolve in parallel with disruption of gut barrier function and host immune homeostasis. Although causality cannot be inferred from the present observational study, these observations strengthen the rationale for future mechanistic investigations exploring microbiome-mediated pathways in AP.

IMO: A clinically distinct phenotype

Among the observations reported by Kumbar et al[1], the higher prevalence of methane-positive breath tests deserves particular attention because recent international consensus statements distinguish IMO from classical hydrogen-predominant SIBO[6,7]. This distinction is biologically important because methane production results predominantly from methanogenic archaea, especially Methanobrevibacter smithii, rather than bacterial species.

Methanogenic microorganisms influence gastrointestinal physiology through methane-mediated slowing of intestinal transit, resulting in prolonged luminal stasis and altered intestinal motility[6,8]. Such mechanisms may be particularly relevant in AP, where paralytic ileus is a frequent complication associated with increased morbidity and delayed clinical recovery. Persistent intestinal hypomotility may, in turn, promote continued microbial overgrowth and prolong impairment of intestinal barrier function, creating a self-perpetuating cycle of dysbiosis and inflammation.

Importantly, recognition of IMO also has therapeutic implications. Methanogenic archaea differ fundamentally from bacteria in their biology and antimicrobial susceptibility, and methane-predominant overgrowth has been associated with lower response rates to conventional antibiotic monotherapy in other gastrointestinal disorders[6]. Although evidence remains limited in AP, future clinical trials should consider stratifying patients according to hydrogen- and methane-predominant breath profiles rather than treating all positive breath tests as a single biological entity. Such phenotype-based stratification may facilitate more individualized therapeutic approaches and improve interpretation of treatment outcomes.

Beyond breath testing: Integrating microbiome science into AP

Breath testing remains a practical and clinically accessible method for identifying intestinal bacterial overgrowth and is appropriately recommended by current clinical guidelines[6,7]. Nevertheless, recent advances in microbiome science increasingly extend beyond the detection of bacterial overgrowth alone. High-throughput sequencing technologies, metagenomic analyses, metabolomic profiling, and functional microbiome assessment now provide opportunities to characterize microbial diversity, metabolic activity, and host-microbiome interactions with substantially greater resolution.

Rather than replacing breath testing, these complementary technologies may enhance understanding of microbial alterations throughout the clinical course of AP. Integrating conventional breath testing with molecular microbiome profiling could identify microbial signatures associated with disease severity, infected pancreatic necrosis, organ failure, and recovery. Such multimodal approaches may ultimately facilitate incorporation of microbiome-derived biomarkers into existing clinical prediction models and contribute to precision medicine strategies in AP.

FUTURE DIRECTIONS

From microbial biomarkers to precision risk stratification

An important question arising from the study by Kumbar et al[1] is whether SIBO represents merely a surrogate marker of severe disease or contributes directly to disease progression. Distinguishing between these possibilities has important clinical implications. If microbial alterations simply reflect the severity of pancreatic inflammation, breath testing may serve primarily as a prognostic biomarker. Conversely, if intestinal microbial dysbiosis actively amplifies systemic inflammation, early identification of microbial disturbances may provide opportunities for targeted therapeutic intervention.

Future prospective studies should therefore evaluate SIBO in conjunction with established prognostic indices, including the Revised Atlanta Classification, Computed Tomography Severity Index, systemic inflammatory response syndrome, and emerging inflammatory biomarkers. Integration of microbial parameters with conventional clinical scoring systems may improve early risk stratification and facilitate identification of patients at greatest risk of persistent organ failure, infected pancreatic necrosis, or prolonged hospitalization[2-5].

Longitudinal evaluation of microbial dynamics

Current evidence regarding SIBO in AP is derived predominantly from cross-sectional assessments performed during hospital admission[1]. However, the intestinal microbiome is highly dynamic and undergoes continuous changes throughout the clinical course of acute inflammatory illness. Serial evaluation of breath test profiles together with longitudinal microbiome analyses may provide valuable insights into the evolution of microbial dysbiosis from the early inflammatory phase through clinical recovery.

Such longitudinal investigations could determine whether persistent microbial alterations identify patients at increased risk of recurrent pancreatitis, delayed gastrointestinal recovery, prolonged nutritional intolerance, or progression to chronic pancreatic dysfunction. Understanding these temporal changes would also help define the optimal timing for microbiome-directed interventions.

Translational implications for microbiome-guided therapy

The growing recognition of host-microbiome interactions in AP has generated considerable interest in microbiome-directed therapeutic strategies. Although routine treatment of SIBO in AP cannot currently be recommended, future interventional studies should move beyond evaluating antimicrobial therapy alone and explore broader approaches aimed at restoring intestinal microbial homeostasis.

Potential strategies include optimization of enteral nutrition, modulation of intestinal motility, microbiome-based nutritional interventions, targeted microbial metabolite modulation, and carefully designed studies evaluating microbiome restoration therapies. Such approaches should ideally be guided by objective microbial characterization rather than empirical treatment alone.

Importantly, advances in multi-omics technologies—including metagenomics, transcriptomics, metabolomics, and proteomics—may facilitate identification of microbial pathways associated with disease progression and therapeutic responsiveness. Integration of these technologies with clinical phenotyping represents an important future direction toward precision medicine in AP.

Research priorities

The study by Kumbar et al[1] establishes an important foundation for future investigations into intestinal microbial alterations in AP. Building upon these findings, future research should prioritize: (1) Prospective multicentre validation of SIBO prevalence across diverse patient populations; (2) Longitudinal assessment of microbial dynamics during disease progression and recovery; (3) Integration of breath testing with culture-independent microbiome profiling techniques; (4) Evaluation of IMO as a distinct clinical phenotype; (5) Development of microbiome-informed prognostic models; and (6) Randomized clinical trials evaluating phenotype-directed microbiome-targeted interventions.

Addressing these priorities may help determine whether intestinal microbial dysbiosis represents a modifiable therapeutic target capable of improving clinical outcomes in AP.

CONCLUSION

The work by Kumbar et al[1] provides important prospective evidence that SIBO is common in patients with AP and is associated with increasing disease severity. Beyond confirming this association, the study highlights the need to better understand the biological significance of intestinal microbial alterations during AP. Emerging concepts surrounding the gut-pancreas axis, IMO, and microbiome-based precision medicine provide opportunities to move beyond descriptive epidemiology toward mechanistic and translational research.

Future studies integrating conventional breath testing with advanced microbiome profiling, longitudinal clinical assessment, and phenotype-directed therapeutic strategies will be essential to determine whether microbial dysbiosis represents a biomarker of disease severity or an actionable contributor to pancreatic inflammation. Such investigations may ultimately facilitate the development of personalized microbiome-informed approaches for the management of AP.

ACKNOWLEDGEMENTS

We thank the authors of the index study for their pioneering work in characterising SIBO burden in AP within the Indian context.